CPSE:NOVO BPharmaceuticals
Novo Nordisk Expands Obesity Pill Reach While Targeting Curative Diabetes Therapies
Novo Nordisk (CPSE:NOVO B) received FDA approval for an oral Wegovy pill for weight management and has launched it in the US with major retail partners.
The company is reporting rapid early prescription uptake for the Wegovy pill soon after launch.
Novo Nordisk expanded its cell therapy collaboration with Aspect Biosystems to pursue potentially curative treatments for diabetes.
Novo Nordisk, best known for its diabetes and obesity treatments, is pushing further into weight management with...